Phase 3 Clinical Trials With Primary Completion Dates in October 2023

This is a list of Phase 3 trials with primary completion dates in October 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
APLMW Apollomics, Inc. 2023-10-01 Phase 3 NCT05054543 Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
ARDS Aridis Pharmaceuticals, Inc. 2023-10-01 Phase 3 NCT05331885 A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
BLCO Bausch + Lomb Corporation 2023-10-01 Phase 3 NCT05360784 "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
CHHE China Health Industries Holdings, Inc. 2023-10-01 Phase 3 NCT04522102 Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase
CORT Corcept Therapeutics Incorporated 2023-10-01 Phase 3 NCT04308590 Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
EIGR Eiger BioPharmaceuticals, Inc. 2023-10-01 Phase 3 NCT04727424 Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
ITCI Intra-Cellular Therapies, Inc. 2023-10-01 Phase 3 NCT05061706 Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
TNXP Tonix Pharmaceuticals Holding Corp. 2023-10-01 Phase 3 NCT05273749 A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia